公开(公告)号：US20250064757A1

公开(公告)日：2025-02-27

申请号：US18629894

申请日：2024-04-08

Applicant: Duke University

Inventor： Kaitlyn ANDREANO ,  Ching-yi CHANG ,  Donald P. MCDONNELL ,  Stephanie L. GAILLARD

IPC: A61K31/138 ,  A61K9/00 ,  A61K9/70 ,  A61K31/00 ,  A61K31/192 ,  A61K31/40 ,  A61K45/06 ,  A61P5/00 ,  A61P35/00 ,  A61P35/04 ,  C12Q1/6827 ,  C12Q1/6886

Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

公开(公告)号：US12115166B2

公开(公告)日：2024-10-15

申请号：US18307718

申请日：2023-04-26

Applicant: Spruce Biosciences, Inc.

Inventor： Alexis Howerton ,  Hal Gerber ,  Michael Huang

IPC: A61K31/5377 ,  A61K9/14 ,  A61K9/48 ,  A61K31/573 ,  A61P5/00 ,  A61P5/24 ,  A61P5/38 ,  C07D487/04

CPC classification number: A61K31/5377 ,  A61K9/14 ,  A61K9/48 ,  A61K9/4825 ,  A61K31/573 ,  A61P5/00 ,  A61P5/24 ,  A61P5/38 ,  C07D487/04 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00

Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

公开(公告)号：US20240115729A1

公开(公告)日：2024-04-11

申请号：US18276111

申请日：2022-02-04

Applicant: University of Virginia Patent Foundation

Inventor： Kimberly A. Kelly, Ph.D. ,  Jessica Hung

IPC: A61K47/69 ,  A61K31/352 ,  A61K45/06 ,  A61K47/58 ,  A61P5/00 ,  C07K7/06

CPC classification number: A61K47/6911 ,  A61K31/352 ,  A61K45/06 ,  A61K47/605 ,  A61P5/00 ,  C07K7/06

Abstract: Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.

公开(公告)号：US11911424B2

公开(公告)日：2024-02-27

申请号：US16961598

申请日：2019-07-24

Applicant: BioGaia AB

Inventor： Stefan Roos ,  Bo Möllstam

IPC: A61K35/747 ,  A61P25/28 ,  A61P5/00 ,  C12N1/20 ,  C12P17/16 ,  C12P19/40 ,  C12R1/225

CPC classification number: A61K35/747 ,  A61P5/00 ,  A61P25/28 ,  C12N1/205 ,  C12P17/165 ,  C12P19/40 ,  C12R2001/225 ,  C12Y301/03031

Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

公开(公告)号：US11896578B2

公开(公告)日：2024-02-13

申请号：US17235468

申请日：2021-04-20

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Alan Glicklich ,  Maria Matilde Sanchez Kam ,  William R. Shanahan

IPC: A61K31/403 ,  A61P17/10 ,  A61P17/06 ,  A61P37/02 ,  A61P19/02 ,  A61P3/10 ,  A61P29/00 ,  A61P35/00 ,  A61K9/20 ,  A61K9/48 ,  A61P5/00

CPC classification number: A61K31/403 ,  A61K9/4825 ,  A61P3/10 ,  A61P5/00 ,  A61P17/06 ,  A61P17/10 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  A61K9/20

Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.

公开(公告)号：US20240024330A1

公开(公告)日：2024-01-25

申请号：US18042748

申请日：2021-08-25

Applicant: Neurocrine Biosciences, Inc.

Inventor： Gordon Raphael Loewen ,  Evan Smith ,  Robert H. Farber ,  Jean L. Chan

IPC: A61K31/5377 ,  A61K47/22 ,  A61K47/10 ,  A61K9/16 ,  A61K9/20 ,  A61K9/10 ,  A61K9/48 ,  A61P5/00

CPC classification number: A61K31/5377 ,  A61K47/22 ,  A61K47/10 ,  A61K9/1652 ,  A61K9/1611 ,  A61K9/1635 ,  A61P5/00 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/10 ,  A61K9/4866 ,  A61K9/2054

Abstract: Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240000785A1

公开(公告)日：2024-01-04

申请号：US18244773

申请日：2023-09-11

Applicant: Kissei Pharmaceutical Co., Ltd.

Inventor： Ernest LOUMAYE ,  Jean-Pierre GOTTELAND ,  Oliver POHL

IPC: A61K31/519 ,  A61P5/00 ,  A61K31/565 ,  A61K31/57

CPC classification number: A61K31/519 ,  A61K31/57 ,  A61K31/565 ,  A61P5/00

Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.

公开(公告)号：US11793760B2

公开(公告)日：2023-10-24

申请号：US18196617

申请日：2023-05-12

Applicant: ESTETRA SRL

Inventor： Séverine Francine Isabelle Jaspart ,  Johannes Jan Platteeuw ,  Denny Johan Marijn Van Den Heuvel

IPC: A61K9/20 ,  A61K9/00 ,  A61K31/565 ,  A61P5/00 ,  A61P15/18 ,  A61K9/16

CPC classification number: A61K9/2095 ,  A61K9/0056 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K31/565 ,  A61P5/00 ,  A61P15/18 ,  A61K9/1623

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 μg of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 μm to 50 μm. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

公开(公告)号：US11759464B2

公开(公告)日：2023-09-19

申请号：US16619702

申请日：2018-06-05

Applicant: ObsEva S.A.

Inventor： Ernest Loumaye ,  Jean-Pierre Gotteland ,  Oliver Pohl

IPC: A61K31/519 ,  A61K31/565 ,  A61P5/00 ,  A61K31/57

CPC classification number: A61K31/519 ,  A61K31/565 ,  A61K31/57 ,  A61P5/00

Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.

公开(公告)号：US11639395B2

公开(公告)日：2023-05-02

申请号：US17087313

申请日：2020-11-02

Applicant: Genentech, Inc.

Inventor： Yung-Hsiang Kao ,  Michael W. Laird ,  Melody Trexler Schmidt ,  Rita L. Wong ,  Daniel P. Hewitt

IPC: C07K16/28 ,  A61K39/395 ,  C07K1/14 ,  A61P5/00 ,  A61P37/02 ,  C07K14/00 ,  C07K16/32 ,  C12N1/38 ,  C07K1/22 ,  C12N5/00

Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.